Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Fusion‐positive non‐small cell lung carcinoma: Biological principles, clinical practice, and diagnostic implications
Daniel Kazdal, Véronique Hofman, Petros Christopoulos, et al.
Genes Chromosomes and Cancer (2022) Vol. 61, Iss. 5, pp. 244-260
Closed Access | Times Cited: 45

Showing 26-50 of 45 citing articles:

A rare case report of a primary lung cancer comprising adenocarcinoma and atypical carcinoid tumor, with the carcinoid component harboring EML4-ALK rearrangement
Wenbin Hu, Jiaming Zhao, Guoxia Wang, et al.
Translational Lung Cancer Research (2024) Vol. 13, Iss. 5, pp. 1150-1162
Open Access | Times Cited: 1
The Advantage of Targeted Next-Generation Sequencing over qPCR in Testing for Druggable EGFR Variants in Non-Small-Cell Lung Cancer
Adam Szpechciński, Joanna Moes-Sosnowska, Paulina Skronska, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 14, pp. 7908-7908
Open Access | Times Cited: 1
State of the Art of Pathologic and Molecular Testing
Sanja Đačić
Hematology/Oncology Clinics of North America (2023) Vol. 37, Iss. 3, pp. 463-473
Closed Access | Times Cited: 3
Liquid biopsies come of age in lung cancer
Petros Christopoulos
Translational Lung Cancer Research (2022) Vol. 11, Iss. 5, pp. 706-710
Open Access | Times Cited: 5
A Real-World Experience from a Single Center (LPCE, Nice, France) Highlights the Urgent Need to Abandon Immunohistochemistry for ROS1 Rearrangement Screening of Advanced Non-Squamous Non-Small Cell Lung Cancer
Véronique Hofman, Samantha Goffinet, Christophe Bontoux, et al.
Journal of Personalized Medicine (2023) Vol. 13, Iss. 5, pp. 810-810
Open Access | Times Cited: 2
Analysis of rare fusions in NSCLC: Genomic architecture and clinical implications
Huriye Seker‐Cin, Timothy Kwang Yong Tay, Daniel Kazdal, et al.
Lung Cancer (2023) Vol. 184, pp. 107317-107317
Closed Access | Times Cited: 2
Clinical Efficacy of Osimertinib in Patients with Advanced Non-Small Cell Lung Cancer and Its Effect on Serum CEA and VEGF Expression
Huanyuan Wang, Xiangwu Zhou, Zhaozhen Wang, et al.
Evidence-based Complementary and Alternative Medicine (2022) Vol. 2022, pp. 1-5
Open Access | Times Cited: 3
RET Proto-Oncogene—Not Such an Obvious Starting Point in Cancer Therapy
Tomasz Kucharczyk, Paweł Krawczyk, Dariusz M. Kowalski, et al.
Cancers (2022) Vol. 14, Iss. 21, pp. 5298-5298
Open Access | Times Cited: 3
Multicenter evaluation of an automated, multiplex, RNA-based molecular assay for detection of ALK, ROS1, RET fusions and MET exon 14 skipping in NSCLC
Linea Melchior, Astrid Hirschmann, Paul Hofman, et al.
Virchows Archiv (2024) Vol. 484, Iss. 4, pp. 677-686
Open Access
Fusion Genes Landscape of Lung Cancer Patients From Inner Mongolia, China
Lan Yu, Jinyang Liu, Jianchao Jia, et al.
Genes Chromosomes and Cancer (2024) Vol. 63, Iss. 7
Closed Access
Clinical utility of circulating tumor DNA profiling in detecting targetable fusions in non-small cell lung cancer
Young-Gon Kim, Boram Lee, Changhee Ha, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access
Locally advanced/metastatic non-small-cell lung cancer in Lebanon: focus on ALK tyrosine kinase inhibitors
Arafat Tfayli, Hady Ghanem, Fadi Nasr, et al.
Future Oncology (2024), pp. 1-11
Closed Access
Advances in the Treatment of Rare Mutations in Non-Small Cell Lung Cancer
Yanning Sun, Li Ma, Xiaofei Zhang, et al.
OncoTargets and Therapy (2024) Vol. Volume 17, pp. 1095-1115
Open Access
Adjuvant crizotinib treatment selected by patient-derived organoids in a patient with stage IIIA adenocarcinoma with novel LRRTM4-ALK fusion: a case report
Bowen Li, Ziqi Jia, Zhicheng Huang, et al.
Translational Lung Cancer Research (2023) Vol. 12, Iss. 11, pp. 2322-2329
Open Access | Times Cited: 1
Lung cancer presenting with central nervous system metastasis: Clinicopathological and molecular analysis of 171 cases
Madeleine Demleitner, Katharina Erlenbach‐Wünsch, Roland Coras, et al.
Annals of Diagnostic Pathology (2022) Vol. 63, pp. 152082-152082
Closed Access | Times Cited: 1
Biomarker MET in tumor pathology
Michaela A. Ihle, Carina Heydt
Deleted Journal (2023) Vol. 44, Iss. 3, pp. 193-196
Open Access
Perspectives in the treatment of less common mutations in patients with non-small cell lung carcinoma
Miloš Pešek
Onkologie (2023) Vol. 17, Iss. 1, pp. 12-15
Closed Access
Response to “NGS, the New Global Standard?”
Sai‐Hong Ignatius Ou, Jin‐Liern Hong, Petros Christopoulos, et al.
Journal of Thoracic Oncology (2023) Vol. 18, Iss. 10, pp. e116-e118
Open Access
EML4-ALK Variant 3a/b as a mechanism of osimertinib resistance in a patient with EGFR L858R positive NSCLC
Teppei Yamaguchi, Katsuhiro Masago, Eiichi Sasaki, et al.
Cancer Genetics (2023) Vol. 280-281, pp. 13-16
Closed Access
Bioinformatics-based prognostic analysis of non-small cell lung cancer
Mingli Zhao, Yunxia Li, Hao Shu, et al.
Research Square (Research Square) (2022)
Open Access
Previous Page - Page 2

Scroll to top